VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO 2022 | Validating ctDNA-based approaches in clinical trials

Marla Lipsyc-Sharf • 4 Jun 2022
ASCO 2022
General
Molecular Profiling

Marla Lipsyc-Sharf, MD, Dana-Farber Cancer Institute, Boston, MA, talks on key challenges associated with the implementation of circulating tumor DNA (ctDNA) and liquid biopsy approaches in clinical practice. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Marla Lipsyc-Sharf

1:46
ctDNA and late recurrence in high-risk, HR+, HER2- breast cancer
Marla Lipsyc-Sharf • 4 Jun 2022
0:25
ctDNA vs. pathological markers
Marla Lipsyc-Sharf • 4 Jun 2022

Related Videos

2:49
Pharmacovigilance and the purpose of clinical trials
Diana Lüftner
2:00
The NCRI: supporting and expediting UK cancer research
Richard Stephens
1:05
Critical data points in the production of biosimilars
Richard Markus
2:31
IO-chemo and IO-radio options for cancer treatment
John Bell

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals